ClinicalTrials.gg
TerminatedNCT00406419STAGEUpdated Nov 27, 2020Results posted

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

A Phase 3 interventional study of Methotrexate and ocrelizumab in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-27.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Why this study was terminated
Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,015
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.

Enrollment
8th of 141
1,015 · median 132
Started
2006
with 12 others
Phase 3
85 of 219
none open now
Registered
25th of 219
by date

Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 8th largest by enrollment of the 141 interventional ones that give a count, is one of 13 that started in 2006, is one of 85 in phase 3, and was the 25th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab or 500mg of i.v. ocrelizumab on Days 1 and 15. A repeat course of i.v. treatment will be administered at Weeks 24 and 26. All patients will receive 7.5mg - 25mg/week concomitant methotrexate at a stable dose. The anticipated time on study treatment is 1-2 years. Target sample size is 1000.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • anti-CD20
  • stage
  • CD20
  • RA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, ≥18 years of age
  • Rheumatoid arthritis for ≥ 3 months
  • Inadequate clinical response to methotrexate at a dose of 7.5-25mg/week for ≥ 12 weeks

Exclusion criteria

Exclusion criteria:

  • Rheumatic disease or inflammatory joint disease, other than RA
  • Prior receipt of any biologic therapy for RA
  • Concurrent treatment with any DMARD (other than methotrexate)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,015 participants (actual)

Study arms

  • Placebo comparator
    Placebo × 2 IV + MTX

    Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.

    Drug: Methotrexate · Drug: Placebo

  • Experimental
    Ocrelizumab 200 mg × 2 IV + MTX

    Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.

    Drug: Methotrexate · Drug: ocrelizumab

  • Placebo comparator
    Ocrelizumab 500 mg × 2 IV + MTX

    Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.

    Drug: Methotrexate · Drug: ocrelizumab

Interventions

  • Methotrexate tablet was administered orally at a dose 7.5-25 mg

  • Ocrelizumab was administered via IV infusion at a dose specified in arm description

  • DrugPlacebo

    Matching placebo to ocrelizumab was administered via IV infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24

    ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).

    Time frame: Week 24

  2. Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 48

    ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).

    Time frame: Week 48

  3. Percentage of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. Pre-existing conditions which worsened during the study were also reported as AEs.

    Time frame: From baseline up to 8.5 years

Secondary outcomes

  1. Percentage of Participants With a Major Clinical Response (ACR70 for ≥ 6 Months) at Week 48

    ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).

    Time frame: Week 48

  2. Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Remission (DAS28 < 2.6) at Weeks 24 and 48

    The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.

    Time frame: Weeks 24 and 48

  3. Change From Baseline in DAS28 at Weeks 24 and 48

    The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.

    Time frame: Weeks 24 and 48

  4. European League Against Rheumatism (EULAR) Response Rates (Categorical DAS Responders) at Weeks 24 and 48

    DAS 28 score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and ESR. DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. EULAR Good response: DAS28 ≤ 3.2 and a change from Baseline \< -1.2. EULAR Moderate response: DAS28 \>3.2 to ≤ 5.1 or a change from Baseline \< -0.6 to ≥ -1.2.

    Time frame: Weeks 24 and 48

  5. Percentage of Participants Achieving an ACR50 Response at Weeks 24 and 48

    ACR50 is defined as 50 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).

    Time frame: Weeks 24 and 48

  6. Percentage of Participants Achieving an ACR70 Response at Weeks 24 and 48

    ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).

    Time frame: Weeks 24 and 48

  7. Percent Change From Baseline in Swollen Joint Count (SJC) at Weeks 24 and 48

    66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66.

    Time frame: Baseline, Week 24, 48

  8. Change From Baseline in Tender Joint Count (TJC) at Weeks 24 and 48

    68 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68.

    Time frame: Baseline, Weeks 24, 48

  9. Change From Baseline in Patient's Pain Visual Analogue Scale (VAS) at Weeks 24 and 48

    The patient assessed their pain on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". A negative change indicated improvement.

    Time frame: Baseline, Week 24, 48

  10. Change From Baseline in Physician's Global VAS at Weeks 24 and 48

    The physician's global assessment of disease activity is assessed on a 0 to 100 millimetres (mm) horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity).

    Time frame: Baseline, Week 24, 48

  11. Change From Baseline in Patient's Global VAS at Weeks 24 and 48

    The patient's global assessment of disease activity is assessed on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 24, 48

  12. Change From Baseline in C-Reactive Protein (CRP) at Weeks 24 and 48

    The serum concentration of C-Reactive Protein (CRP) is measured in milligrams per deciliter (mg/dL). A reduction in the level is considered an improvement.

    Time frame: Baseline, Week 24, 48

  13. Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Weeks 24 and 48

    HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.

    Time frame: Baseline, Week 24, 48

  14. Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) at Weeks 24 and 48

    HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.

    Time frame: Baseline, Week 24, 48

  15. Change From Baseline in the Modified Total Sharp Score (mTSS) at Weeks 24 and 48

    mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Baseline, Week 24, 48

  16. Change From Baseline in Modified Erosion Score at Weeks 24 and 48

    The erosion score is a summary of erosion severity in 32 joints of the hands (16 joints per hand) and 12 joints in the feet (6 joints per foot). Each joint is scored, according to the surface area involved, from 0 to 5, with 5 indicating extensive loss of bone from more than one-half of the articulating bone (0 indicates no erosion). Because each side of a foot joint is graded separately on this scale, the maximum erosion score for a foot joint is 10. The maximal erosion score is 280.

    Time frame: Baseline, Week 24, 48

  17. Change From Baseline in Modified Joint Space Narrowing Score at Weeks 24 and 48

    The joint space narrowing score summarizes the severity of joint space narrowing in 30 joints of the hands and 12 joints of the feet. Assessment of joint space narrowing for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no/normal joint space narrowing and 4 indicating complete loss of joint space, bony ankylosis, or luxation. The maximum joint space narrowing score is 168.

    Time frame: Baseline, Week 24, 48

  18. Percentage of Participants Without Radiographic Progression Defined as Change in mTSS ≤ 0 at Weeks 24 and 48

    Radiographic progression was defined as a change of ≤ 0 in the total Genant-modified Sharp score. The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage.

    Time frame: Weeks 24, 48

  19. Percentage of Participants With a Reduction in Modified Total Sharp Score (mTSS) From Baseline at Week 48

    mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Baseline, Week 48

  20. Percentage of Participants With a Reduction of Greater Than or Equal to 0.25 Units in the HAQ-DI Score at Weeks 24 and

    HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.

    Time frame: Week 24, 48

  21. Change From Baseline in Short Form Health Survey (SF-36) Subscale and Summary Scores at Weeks 24 and 48

    The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical and Mental Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

    Time frame: Baseline, Week 24, 48

  22. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Fatigue Assessment at Weeks 24 and 48

    The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.

    Time frame: Baseline, Week 24, 48

  23. Change From Baseline in Pain Quality and Impact of Pain on Daily Function Measured by the Brief Pain Inventory (BPI) Short Form at Weeks 24 and 48

    The modified BPI (short-form) is a short questionnaire to assess the severity of pain and the impact of pain on daily functions. The first two questions relate to average and current pain respectively and are assessed on a scale from 0 to 10, where 0 represents no pain, and 10 represents pain as bad as one can imagine. The degree to which pain has interfered with 7 different aspects is also rated on a scale from 0 to 10, where 0 represents that pain does not interfere and 10 that pain completely interferes.

    Time frame: Baseline, Week 24, 48

07

Results

Posted Nov 27, 2020

Participant flow

Participant flow — Overall Study
MilestonePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Started324344347
Completed000
Not completed324344347
Withdrew: Death314
Withdrew: Protocol violation625
Withdrew: Study terminated by sponsor260288282
Withdrew: Withdrawal by subject172426
Withdrew: Lack of efficacy1216
Withdrew: Non-compliance with study drug563
Withdrew: Adverse event101216
Withdrew: Lost to follow-up11105

Outcome measures

PrimaryPercentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24

ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24
Percentage of participantsPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 2435.7 (30.5 to 41.0)56.9 (51.6 to 62.1)54.5 (49.2 to 59.8)
Statistical analysis
  • Placebo × 2 IV + MTX vs Ocrelizumab 200 mg × 2 IV + MTX · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 18.5 · 95% CI 11 to 25.9
  • Placebo × 2 IV + MTX vs Ocrelizumab 500 mg × 2 IV + MTX · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 21.4 · 95% CI 14.1 to 28.8
PrimaryPercentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 48

ACR20 is defined as 20 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 48
Percentage of participantsPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 4827.6 (22.7 to 32.5)58.3 (53.1 to 63.5)62.1 (57.0 to 67.2)
Statistical analysis
  • Placebo × 2 IV + MTX vs Ocrelizumab 200 mg × 2 IV + MTX · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 30.8 · 95% CI 23.7 to 37.9
  • Placebo × 2 IV + MTX vs Ocrelizumab 500 mg × 2 IV + MTX · Cochran-Mantel-Haenszel · p = < 0.0001 · Weighted difference: 34.5 · 95% CI 27.4 to 41.5
PrimaryPercentage of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. Pre-existing conditions which worsened during the study were also reported as AEs.

Time frame:
From baseline up to 8.5 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs)
Percentage of participantsPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Percentage of Participants With Adverse Events (AEs)79.482.283.7
SecondaryPercentage of Participants With a Major Clinical Response (ACR70 for ≥ 6 Months) at Week 48

ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With a Major Clinical Response (ACR70 for ≥ 6 Months) at Week 48
Percentage of participantsPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Percentage of Participants With a Major Clinical Response (ACR70 for ≥ 6 Months) at Week 480.9 (0.0 to 2.0)6.1 (3.6 to 8.7)7.3 (4.5 to 10.0)
SecondaryPercentage of Participants Achieving Disease Activity Score 28 (DAS28) Remission (DAS28 < 2.6) at Weeks 24 and 48

The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.

Time frame:
Weeks 24 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Remission (DAS28 < 2.6) at Weeks 24 and 48
Percentage of participantsPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Week 245.3 (2.9 to 7.8)7.9 (5.0 to 10.7)10.8 (7.5 to 14.1)
Week 485.3 (2.9 to 7.8)16.0 (12.2 to 19.9)17.5 (13.5 to 21.5)
SecondaryChange From Baseline in DAS28 at Weeks 24 and 48

The Disease Activity Score (DAS28) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and Erythrocyte Sedimentation Rate (ESR). DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.

Time frame:
Weeks 24 and 48
Reported as:
Mean · Units on a Scale
Change From Baseline in DAS28 at Weeks 24 and 48
Units on a ScalePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Baseline6.42 ± 1.1036.40 ± 1.1436.40 ± 1.077
Change at Week-1.33 ± 1.329-2.00 ± 1.248-2.02 ± 1.310
Change at Week 48-1.38 ± 1.290-2.42 ± 1.504-2.68 ± 1.475
SecondaryEuropean League Against Rheumatism (EULAR) Response Rates (Categorical DAS Responders) at Weeks 24 and 48

DAS 28 score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and ESR. DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. EULAR Good response: DAS28 ≤ 3.2 and a change from Baseline \< -1.2. EULAR Moderate response: DAS28 \>3.2 to ≤ 5.1 or a change from Baseline \< -0.6 to ≥ -1.2.

Time frame:
Weeks 24 and 48
Reported as:
Number · Percentage of participants
European League Against Rheumatism (EULAR) Response Rates (Categorical DAS Responders) at Weeks 24 and 48
Percentage of participantsPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Week 2441.668.870.0
Week 4835.365.972.0
SecondaryPercentage of Participants Achieving an ACR50 Response at Weeks 24 and 48

ACR50 is defined as 50 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).

Time frame:
Weeks 24 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an ACR50 Response at Weeks 24 and 48
Percentage of participantsPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Week 2416.3 (12.2 to 20.4)31.8 (26.9 to 36.7)31.2 (26.3 to 36.1)
Week 4812.9 (9.2 to 16.5)39.9 (34.8 to 45.1)36.7 (31.6 to 41.8)
SecondaryPercentage of Participants Achieving an ACR70 Response at Weeks 24 and 48

ACR70 is defined as 70 percent improvement respectively in: a) swollen joint count (SJC) and tender joint count (TJC) and b) Three of the following 5 assessments: Subject's global assessment of pain by VAS Subject's global assessment of disease activity (VAS) Investigator/Physician's global assessment of disease activity (VAS) Subject's assessment of disability measured by HAQ-DI Acute phase reactant (ESR or CRP).

Time frame:
Weeks 24 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an ACR70 Response at Weeks 24 and 48
Percentage of participantsPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Week 245.6 (3.1 to 8.2)14.3 (10.6 to 18.0)12.2 (8.8 to 15.7)
Week 486.6 (3.8 to 9.3)20.7 (16.4 to 25.0)22.4 (18.0 to 26.9)
SecondaryPercent Change From Baseline in Swollen Joint Count (SJC) at Weeks 24 and 48

66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66.

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Percentage of Change
Percent Change From Baseline in Swollen Joint Count (SJC) at Weeks 24 and 48
Percentage of ChangePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Change at Week 24-38.20 ± 66.127-51.82 ± 80.805-54.76 ± 39.896
Change at Week 48-39.39 ± 59.184-61.36 ± 44.414-64.22 ± 65.234
SecondaryChange From Baseline in Tender Joint Count (TJC) at Weeks 24 and 48

68 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68.

Time frame:
Baseline, Weeks 24, 48
Reported as:
Mean · Tendor joins
Change From Baseline in Tender Joint Count (TJC) at Weeks 24 and 48
Tendor joinsPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Change at Week 24-36.97 ± 58.675-55.11 ± 37.962-51.07 ± 49.700
Change at Week 48-35.91 ± 64.358-61.51 ± 37.229-59.55 ± 48.474
SecondaryChange From Baseline in Patient's Pain Visual Analogue Scale (VAS) at Weeks 24 and 48

The patient assessed their pain on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". A negative change indicated improvement.

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Units on scale
Change From Baseline in Patient's Pain Visual Analogue Scale (VAS) at Weeks 24 and 48
Units on scalePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Change at Week 24-9.10 ± 109.646-32.02 ± 88.637-27.73 ± 139.732
Change at Week 48-2.28 ± 148.933-38.86 ± 104.267-32.47 ± 197.692
SecondaryChange From Baseline in Physician's Global VAS at Weeks 24 and 48

The physician's global assessment of disease activity is assessed on a 0 to 100 millimetres (mm) horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity).

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Units on scale
Change From Baseline in Physician's Global VAS at Weeks 24 and 48
Units on scalePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Change at Week 24-40.23 ± 39.655-51.44 ± 34.669-53.02 ± 34.479
Change at Week 48-41.60 ± 43.285-61.29 ± 31.543-62.10 ± 30.866
SecondaryChange From Baseline in Patient's Global VAS at Weeks 24 and 48

The patient's global assessment of disease activity is assessed on a 0 to 100 millimeters (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Units on scale
Change From Baseline in Patient's Global VAS at Weeks 24 and 48
Units on scalePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Change at Week 24-20.73 ± 74.480-37.96 ± 83.908-36.99 ± 79.130
Change at Week 48-17.13 ± 100.706-42.02 ± 103.526-55.26 ± 37.873
SecondaryChange From Baseline in C-Reactive Protein (CRP) at Weeks 24 and 48

The serum concentration of C-Reactive Protein (CRP) is measured in milligrams per deciliter (mg/dL). A reduction in the level is considered an improvement.

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Milligrams per deciliter (mg/dL)
Change From Baseline in C-Reactive Protein (CRP) at Weeks 24 and 48
Milligrams per deciliter (mg/dL)Placebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Change at Week 2411.64 ± 116.697-30.41 ± 109.193-23.07 ± 109.193
Change at Week 4822.01 ± 190.346-40.89 ± 90.13915.14 ± 820.007
SecondaryChange From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Weeks 24 and 48

HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Percentage Change from Baseline
Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Weeks 24 and 48
Percentage Change from BaselinePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Change at Week 24-20.11 ± 48.921-30.12 ± 86.217-40.83 ± 38.243
Change at Week 48-22.67 ± 57.893-35.47 ± 78.670-45.63 ± 39.241
SecondaryChange From Baseline in the Erythrocyte Sedimentation Rate (ESR) at Weeks 24 and 48

HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Percentage Change from Baseline
Change From Baseline in the Erythrocyte Sedimentation Rate (ESR) at Weeks 24 and 48
Percentage Change from BaselinePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Change at Week 24-2.51 ± 66.453-20.10 ± 90.059-29.98 ± 57.195
Change at Week 48-2.72 ± 57.893-27.24 ± 147.973-41.19 ± 55.485
SecondaryChange From Baseline in the Modified Total Sharp Score (mTSS) at Weeks 24 and 48

mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Units on scale
Change From Baseline in the Modified Total Sharp Score (mTSS) at Weeks 24 and 48
Units on scalePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Baseline33.58 ± 51.10631.45 ± 51.32331.99 ± 49.602
Change at Week 241.04 ± 2.8420.34 ± 2.424-0.03 ± 2.534
Change at Week 481.74 ± 5.2930.26 ± 2.791-0.03 ± 2.911
SecondaryChange From Baseline in Modified Erosion Score at Weeks 24 and 48

The erosion score is a summary of erosion severity in 32 joints of the hands (16 joints per hand) and 12 joints in the feet (6 joints per foot). Each joint is scored, according to the surface area involved, from 0 to 5, with 5 indicating extensive loss of bone from more than one-half of the articulating bone (0 indicates no erosion). Because each side of a foot joint is graded separately on this scale, the maximum erosion score for a foot joint is 10. The maximal erosion score is 280.

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Units on scale
Change From Baseline in Modified Erosion Score at Weeks 24 and 48
Units on scalePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Baseline17.10 ± 27.25616.22 ± 27.87516.24 ± 26.103
Change at Week 240.61 ± 1.7780.18 ± 1.4870.04 ± 1.511
Change at week 481.06 ± 3.2380.08 ± 1.690-0.08 ± 1.588
SecondaryChange From Baseline in Modified Joint Space Narrowing Score at Weeks 24 and 48

The joint space narrowing score summarizes the severity of joint space narrowing in 30 joints of the hands and 12 joints of the feet. Assessment of joint space narrowing for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no/normal joint space narrowing and 4 indicating complete loss of joint space, bony ankylosis, or luxation. The maximum joint space narrowing score is 168.

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Units on scale
Change From Baseline in Modified Joint Space Narrowing Score at Weeks 24 and 48
Units on scalePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Baseline16.47 ± 25.99015.22 ± 25.01215.75 ± 25.118
Change at Week 240.43 ± 1.6540.16 ± 1.655-0.07 ± 1.504
Change at Week 480.68 ± 2.7770.18 ± 1.4710.05 ± 1.859
SecondaryPercentage of Participants Without Radiographic Progression Defined as Change in mTSS ≤ 0 at Weeks 24 and 48

Radiographic progression was defined as a change of ≤ 0 in the total Genant-modified Sharp score. The Genant-modified Sharp scoring system assesses structural damage due to rheumatoid arthritis in radiographs. A score for erosions of 0-3.5 (8 gradations) is assigned for 14 joints in each hand and wrist, and 6 joints in each foot. Joint space narrowing scores of 0-4 (9 gradations) are assigned to 13 joints in each hand and 6 joints in each foot. The maximum erosion score is 40 x 3.5 = 140. The maximum joint space narrowing score is 38 x 4.0 = 152. Both the erosion and joint space narrowing scores are normalized to 145 and are added together for a maximum total Genant-modified Sharp score of 290; the minimum score is 0. A higher score indicates more damage.

Time frame:
Weeks 24, 48
Reported as:
Number · Percentage of Participants
Percentage of Participants Without Radiographic Progression Defined as Change in mTSS ≤ 0 at Weeks 24 and 48
Percentage of ParticipantsPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Week 2447.5 (41.9 to 53.1)58.7 (53.3 to 64.1)65.3 (60.2 to 70.5)
Week 4837.7 (32.3 to 43.1)58.7 (53.3 to 64.1)60.8 (55.5 to 66.1)
SecondaryPercentage of Participants With a Reduction in Modified Total Sharp Score (mTSS) From Baseline at Week 48

mTSS: measure of joint damage that combines scores for bone erosion and joint space narrowing (JNS). Erosion score: total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=normal to 3.5=very severe erosion. JNS score: total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=normal to 4.0=definite ankylosis (stiffness or fixation of a joint). mTSS scores ranged from 0 (normal) to 292 (worst possible total score). Change= mTSS score at Week 24 minus score at baseline. An increase in mTSS from baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Baseline, Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Reduction in Modified Total Sharp Score (mTSS) From Baseline at Week 48
Percentage of ParticipantsPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Percentage of Participants With a Reduction in Modified Total Sharp Score (mTSS) From Baseline at Week 4811.8 (8.2 to 15.4)22.7 (18.1 to 27.2)29.8 (24.8 to 34.7)
SecondaryPercentage of Participants With a Reduction of Greater Than or Equal to 0.25 Units in the HAQ-DI Score at Weeks 24 and

HAQ-DI is a self-completed patient questionnaire specific for Rheumatoid Arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ-DI the patient must have a domain score for at least 6 of 8 domains. The HAQ-DI is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.

Time frame:
Week 24, 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Reduction of Greater Than or Equal to 0.25 Units in the HAQ-DI Score at Weeks 24 and
Percentage of ParticipantsPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Week 2442.3 (36.9 to 47.7)59.8 (54.6 to 65.0)66.5 (61.5 to 71.5)
Week 4834.8 (29.6 to 40.0)58.9 (53.7 to 64.1)65.9 (60.9 to 70.9)
SecondaryChange From Baseline in Short Form Health Survey (SF-36) Subscale and Summary Scores at Weeks 24 and 48

The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical and Mental Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Units on scale
Change From Baseline in Short Form Health Survey (SF-36) Subscale and Summary Scores at Weeks 24 and 48
Units on scalePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Baseline: Mental Component Summary40.54 ± 12.28239.99 ± 11.86340.48 ± 12.822
Change at Week 24: Mental Component Summary4.38 ± 10.8866.11 ± 10.0825.80 ± 11.224
Change at Week 48: Mental Component Summary4.15 ± 10.3266.36 ± 10.2126.43 ± 11.795
Baseline: Physical Component Summary31.86 ± 7.38732.24 ± 7.40131.58 ± 8.039
Change at Week 24: Physical Component Summary5.29 ± 8.4216.73 ± 8.3857.71 ± 7.328
Change at Week 48: Physical Component Summary5.28 ± 8.3738.38 ± 8.3479.15 ± 8.389
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Fatigue Assessment at Weeks 24 and 48

The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Units on scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Fatigue Assessment at Weeks 24 and 48
Units on scalePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Baseline27.25 ± 10.82126.87 ± 10.92026.57 ± 11.194
Change at Week 245.14 ± 9.8647.18 ± 9.7557.07 ± 10.269
Change at Week 485.39 ± 10.0548.01 ± 10.1328.41 ± 10.682
SecondaryChange From Baseline in Pain Quality and Impact of Pain on Daily Function Measured by the Brief Pain Inventory (BPI) Short Form at Weeks 24 and 48

The modified BPI (short-form) is a short questionnaire to assess the severity of pain and the impact of pain on daily functions. The first two questions relate to average and current pain respectively and are assessed on a scale from 0 to 10, where 0 represents no pain, and 10 represents pain as bad as one can imagine. The degree to which pain has interfered with 7 different aspects is also rated on a scale from 0 to 10, where 0 represents that pain does not interfere and 10 that pain completely interferes.

Time frame:
Baseline, Week 24, 48
Reported as:
Mean · Units on scale
Change From Baseline in Pain Quality and Impact of Pain on Daily Function Measured by the Brief Pain Inventory (BPI) Short Form at Weeks 24 and 48
Units on scalePlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Baseline: average pain6.39 ± 2.0116.28 ± 2.0776.42 ± 2.194
Baseline: pain right now5.57 ± 2.3985.75 ± 2.4955.82 ± 2.533
Change at Week 24: average pain-1.82 ± 2.441-2.45 ± 2.299-2.48 ± 2.424
Change at Week 24: pain right now-1.57 ± 2.775-2.32 ± 2.659-2.24 ± 2.671
Change at Week 48: average pain-1.78 ± 2.619-2.92 ± 2.442-3.06 ± 2.422
Change at Week 48: pain right now-1.53 ± 2.795-2.66 ± 2.676-2.92 ± 2.681

Adverse events

Collected over Baseline up to 33 months.. Non-serious events are listed at a 0.05% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo × 2 IV + MTX5/318 (1.6%)73/318 (23%)228/318 (71.7%)
Ocrelizumab 200 mg × 2 IV + MTX2/343 (0.6%)61/343 (17.8%)272/343 (79.3%)
Ocrelizumab 500 mg × 2 IV + MTX8/345 (2.3%)78/345 (22.6%)273/345 (79.1%)
Most frequent serious events
Showing 10 of 192
Most frequent serious events
EventPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
PneumoniaInfections and infestations3/3184/34310/345
Rheumatoid arthritisMusculoskeletal and connective tissue disorders4/3181/3432/345
Urinary tract infectionInfections and infestations4/3181/3433/345
SepsisInfections and infestations4/3181/3430/345
Myocardial infarctionCardiac disorders3/3181/3432/345
CellulitisInfections and infestations3/3181/3433/345
Pyelonephritis acuteInfections and infestations3/3180/3431/345
Humerus fractureInjury, poisoning and procedural complications0/3183/3431/345
VomitingGastrointestinal disorders2/3183/3431/345
Renal failure acuteRenal and urinary disorders2/3183/3431/345
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlacebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTX
Infusion related reactionInjury, poisoning and procedural complications62/31889/34396/345
Upper respiratory tract infectionInfections and infestations64/31879/34385/345
NasopharyngitisInfections and infestations45/31843/34351/345
Urinary tract infectionInfections and infestations40/31838/34348/345
BronchitisInfections and infestations39/31843/34340/345
HypertensionVascular disorders26/31842/34337/345
SinusitisInfections and infestations18/31833/34328/345
HeadacheNervous system disorders24/31829/34332/345
InfluenzaInfections and infestations20/31831/34329/345
Back painMusculoskeletal and connective tissue disorders16/31819/34326/345

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTXTotal
Mean50.5 ± 11.5451.8 ± 11.9750.9 ± 12.2351.1 ± 11.91
Sex: Female, Male
Sex: Female, Male(Participants)Placebo × 2 IV + MTXOcrelizumab 200 mg × 2 IV + MTXOcrelizumab 500 mg × 2 IV + MTXTotal
Female248283282813
Male726061193
08

Study locations

1 site
  • Trial Information Support Line
    South San Francisco, California 94080, United States
09

References and documents

Publications

  • Emery P, Rigby W, Tak PP, Dorner T, Olech E, Martin C, Millar L, Travers H, Fisheleva E. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One. 2014 Feb 3;9(2):e87379. doi: 10.1371/journal.pone.0087379. eCollection 2014. PubMed 24498318 ↗
  • Rigby W, Tony HP, Oelke K, Combe B, Laster A, von Muhlen CA, Fisheleva E, Martin C, Travers H, Dummer W. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 2012 Feb;64(2):350-9. doi: 10.1002/art.33317. PubMed 21905001 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2006 to primary completion in Oct 2009, 33 months.

Results were first posted in Nov 2020, 11 years 1 month after primary completion. A results delay was requested in Jun 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2006
First posted
Dec 4, 2006
StartActual
Dec 27, 2006
Primary completionActual
Oct 6, 2009
CompletionActual
Apr 22, 2015
Results delay requested
Jun 28, 2013
Results first posted
Nov 27, 2020
Last update
Nov 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00406419
Lead sponsor
Genentech, Inc.
Collaborators
Roche Pharma AG
Responsible party
Sponsor
First posted
Dec 4, 2006
Start date
Dec 27, 2006
Primary completion
Oct 6, 2009
Completion
Apr 22, 2015
Results posted
Nov 27, 2020
Last update
Nov 27, 2020

Study contacts

Wolfgang Dummer, M.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion